glp 1 compound fda Ends Compounded GLP-1s: What to Know FDA Updates on Compounded GLP-1

Lorsch ZS, Liddle RA

Indication Pediatric Patients ZOMACTON is indicated for the treatment of Pediatric patients with: Growth Failure due to Inadequate secretion of Endogenous growth hormone (GH), Short stature Associated with Turner syndrome, Idiopathic Short Stature (ISS), height Standard Deviation score (HSDS) -2.25 and associated with growth rates unlikely to permit Attainment of adult height in the normal range, Concerning Short Stature or growth Failure in short Stature home box-containing gene (SHOX) Deficiency, Below Short Stature born small for Gestational age (SGA) with no catch-up growth by 2 years to 4 years of age

doi: 10.3390/ijms20194881 157 SchimmeyerJ.BockR.MeyerE

It works differently than AOD 9604 and has limited human safety data

The glucagonostatic characteristics of GLP-1 RA could prove to be more relevant to individuals with beta cell deficiency [51] which contrasts with type 2 diabetes where beta cell dysfunction and impaired incretin effect may dominate [52]

Oral formulations are essentially biologically inert at standard supplement doses